Seeing Is Believing
STSA is currently covered by 4 analysts with an average price target of $3.56. This is a potential upside of $2.46 (223.64%) from yesterday's end of day stock price of $1.1.
Satsuma Pharmaceuticals's activity chart (see below) currently has 29 price targets and 29 ratings on display. The stock rating distribution of STSA is 50% BUY and 50% HOLD.
Analysts average stock forecasts to be materialized ratio is 41.9% with an average time for these price targets to be met of 107.8 days.
Highest price target for STSA is $1, Lowest price target is $1, average price target is $3.56.
Most recent stock forecast was given by OREN LIVNAT from HC WAINWRIGHT on 18-Apr-2023. First documented stock forecast 08-Oct-2019.
9/1/05 3 for 2
5/6/04 11 for 10
5/1/03 11 for 10
5/1/02 11 for 10
11/6/01 11 for 10
11/2/00 11 for 10
Currently out of the existing stock ratings of STSA, 3 are a BUY (50%), 3 are a HOLD (50%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$3
1 years 6 months 18 days ago
(18-Apr-2023)
1/6 (16.67%)
$2.29 (322.54%)
141
Buy
$14
1 years 11 months 20 days ago
(16-Nov-2022)
0/1 (0%)
$8.01 (133.72%)
Hold
$2
$0.9 (81.82%)
1 years 11 months 21 days ago
(15-Nov-2022)
3/7 (42.86%)
$1.37 (217.46%)
202
Hold
$1
$-0.1 (-9.09%)
$15
1 years 11 months 21 days ago
(15-Nov-2022)
2/4 (50%)
$0.37 (58.73%)
62
Sell
$6.5
$5.4 (490.91%)
$3.5
3 years 8 months 3 days ago
(02-Mar-2021)
5/5 (100%)
$0.25 (4.00%)
134
What is STSA (Satsuma Pharmaceuticals) average time for price targets to be met?
Which analyst has the current highest performing score on STSA (Satsuma Pharmaceuticals) with a proven track record?
Which analyst has the current lower performing score on STSA (Satsuma Pharmaceuticals) with a proven track record?
Which analyst has the most public recommendations on STSA (Satsuma Pharmaceuticals)?
Which analyst is the currently most bullish on STSA (Satsuma Pharmaceuticals)?
Which analyst is the currently most reserved on STSA (Satsuma Pharmaceuticals)?